Review: Cannabinoids control chemotherapy-induced nausea and vomiting but increase the risk for side effects

January 2002
ACP Journal Club;Jan/Feb2002, Vol. 136 Issue 1, p19
Academic Journal
Presents an abstract of the study 'Cannabinoids for Control of Chemotherapy Induced Nausea and Vomiting: Quantitative Systemic Review,' by M. R. Tramèr, D. Carroll, F. A. Campbell, et al., published on the July 7, 2001 issue of the 'British Medical Journal.' Comment on the study.


Related Articles

  • The emerging role of cannabinoid neuromodulators in symptom management. Mellar Davis // Supportive Care in Cancer;Jan2007, Vol. 15 Issue 1, p63 

    Abstract Introduction?? The cannabinoids nabilone (Cesamet) and dronabinol (Marinol) are indicated for the management of chemotherapy-induced nausea and vomiting (CINV) in cancer patients who have failed to respond adequately to conventional antiemetic therapy. Discussion?? The endocannabinoid...

  • nabilone.  // Royal Society of Medicine: Medicines;2002, p381 

    The article presents information on the cannabinoid nabilone. It is a drug derived from cannabis. The drug can be used to relieve toxic side-effects, which include nausea and vomiting associated with chemotherapy. It has significant side-effects such as euphoria, dizziness, vertigo and dry...

  • The cost of chemotherapy-induced nausea and vomiting in Italy. Enzo Ballatori; Fausto Roila; Benedetta Ruggeri; Stella Porrozzi; Mauro Iannopollo; Giancarla Soru; Giorgio Cruciani; Bruno Daniele; Maria Locatelli; James Pellissier; Robert Deuson // Supportive Care in Cancer;Jan2007, Vol. 15 Issue 1, p31 

    Abstract Goals of work?? The aim of this paper is to analyze the costs of chemotherapy-induced nausea and vomiting (CINV) in Italy. Materials and methods?? In this prospective observational study at seven public oncology centers, incidence and intensity of CINV daily for 8?days after...

  • Role of dexamethasone dosage in combination with 5-HT3 antagonists for prophylaxis of acute chemotherapy-induced nausea and vomiting. Münstedt, K; Müller, H; Blauth-Eckmeyer, E; Stenger, K; Zygmunt, M; Vahrson, H // British Journal of Cancer;2/1/99, Vol. 79 Issue 3/4, p637 

    Dexamethasone (20 mg) or its equivalent in combination with 5-HT[SUB3] antagonists appears to be the gold-standard dose for antiemetic prophylaxis. Additional to concerns about the use of corticosteroids with respect to enhanced tumour growth or impaired killing of the tumour cells, there is...

  • New Generation Agents for the Prevention of Chemotherapy-Induced Nausea and Vomiting. Sankhala, Kamalesh K.; Karnad, Anand B. // European Journal of Clinical & Medical Oncology;2011, Vol. 3 Issue 3, p10 

    Chemotherapy-induced nausea and vomiting (CINV) is associated with a significant decline in quality of life in cancer patients. The morbidity due to CINV depends on the chemotherapeutic agent, the number of repeated cycles of treatment, and patient characteristics. Discontinuation of...

  • Mechanisms of Broad-Spectrum Antiemetic Efficacy of Cannabinoids against Chemotherapy-Induced Acute and Delayed Vomiting. Darmani, Nissar A. // Pharmaceuticals;Sep2010, Vol. 3 Issue 9, p2930 

    Chemotherapy-induced nausea and vomiting (CINV) is a complex pathophysiological condition and consists of two phases. The conventional CINV neurotransmitter hypothesis suggests that the immediate phase is mainly due to release of serotonin (5-HT) from the enterochromaffin cells in the...

  • Prevention and treatment of chemotherapy-induced nausea and vomiting: A review. Margarita V. DiVall; Cersosimo, Robert J. // Formulary;Jun2007, Vol. 42 Issue 6, p378 

    Nausea and vomiting (emesis) are among the most distressing side effects of chemotherapy and are associated with significant clinical consequences and decreased health-related quality of life. The likelihood, severity, and duration of nausea and vomiting depend largely on the emetogenic...

  • Antiemetics in children receiving chemotherapy. MASCC/ESMO guideline update 2009. Jordan, Karin; Roila, Fausto; Molassiotis, Alexander; Maranzano, Ernesto; Clark-Snow, Rebecca; Feyer, Petra // Supportive Care in Cancer;Mar2011, Vol. 19, p37 

    Only a few studies have been carried out in children on the prevention of chemotherapy-induced nausea and vomiting (CINV). 5-HT receptor antagonists have been shown to be more efficacious and less toxic than metoclopramide, phenothiazines and cannabinoids. Most dose studies are available for the...

  • A phase II dose-ranging study of palonosetron in Japanese patients receiving moderately emetogenic chemotherapy, including anthracycline and cyclophosphamide-based chemotherapy. Segawa, Y.; Aogi, K.; Inoue, K.; Sano, M.; Sekine, I.; Tokuda, Y.; Isobe, H.; Ogura, T.; Tsuboi, M.; Atagi, S. // Annals of Oncology;Nov2009, Vol. 20 Issue 11, p1874 

    Background: The 5-HT3 receptor antagonists (RAs) help maintain the standard of care, in various combinations with other agents, for prevention of chemotherapy-induced nausea and vomiting (CINV). Palonosetron is a new generation 5-HT3 RA with indication not only acute but also delayed nausea and...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics